1.Leyva R, Perera A, Morín JA. Radiofármacos en inmunocentelleografía y
radioinmunoterapia. Nucleus. 2012;52:68–71.
2.Peña Y, Perera A, Batista JF. Immunoscintigraphy and radioimmunotherapy in Cuba: experiences with labeled monoclonal antibodies for cancer diagnosisand treatment (1993–2013). MEDICC Rev. 2014;16:55–60.
3.Torres LA, Coca MA, Batista JF, et al. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidermal growth factor receptor, nimotuzumab, in the loco regional treatment of malignant gliomas. Nucl Med Commun. 2008;29:66–75.
4.Immunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer.
Quián YP, Crombet T, Batista JF, Prats A, Perera A. Clin Nucl Med. 2016 Mar;41(3):244-6.
5.A phase I study of 99mTc-hR3 (DiaCIM1), a humanized immunoconjugate directed towards the epidermal growth factor receptor
K.A. VALLIS, R.M. REILLY, P. CHEN,A. OZA, A. HENDLER,
R. CAMERON, et al. Nuclear Medicine Communications, 2002, 23, 1155±1164
6.Biodistribution of 99mTc-Labeled Anti-Human Epidermal
Growth Factor Receptor (EGF-R) Humanized Monoclonal
Antibody h-R3 in a Xenograft Model of Human Lung Adenocarcinoma
Alejo Morales-Morales, Jorge Duconge´,Idania Caballero-Torres,
Gilda Nuñez-Gandolff,et al.. Nuclear Medicine & Biology, Vol. 26, pp. 275–279, 1999
7.Freeze-Dried Formulation for Direct 99mTc-Labeling ior-egf/r3
MAb: Additives, Biodistribution, and Stability. Alejo A. Morales Morales, Gilda Nuñez-Gandolff, Niuvis Pérez, et al. Nuclear Medicine & Biology, Vol. 26, pp. 717–723, 1999
8.Humanized versus Murine Anti-human Epidermal Growth Factor Receptor Monoclonal Antibodies for Immunoscintigraphic Studies. Alejo A. Morales Morales, Jorge Duconge´, Daniel Alvarez-Ruiz, Maria de Los Angeles Becquer-Viart, et al.. Nuclear Medicine & Biology, Vol. 27, pp. 199–206, 2000